Correlation of integrin β3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma

Table 1 Correlation of integrin β3 mRNA, VEGF protein and MDV with clinicopathological features

Clinicopathological parameters	n	Integrinβ3 mRNA	VEGF							MVD
		-	+ - +++	χ2	P	-	+ - +++	χ2	P	n/mm2	t	P
Growth pattern	118			8.42	< 0.01			10.44	< 0.01		3.92	< 0.01
Expansive	51	32	19			32	19			49.45 ± 21.72
Infiltrative	67	24	43			22	45			64.06 ± 18.76
Histological grade (G)				6.47	< 0.05			3.49	0.062		1.25	> 0.05
G1 + G2	70	40	30			37	33			55.72 ± 21.56
G3 + G4	48	16	32			17	31			60.70 ± 20.73
Invasive depth				26.60	< 0.01			34.19	< 0.01		6.41	< 0.01
T1-T2	47	36	11			37	10			44.42 ± 19.96
T3-T4	71	20	51			17	54			66.56 ± 17.23
Vessel invasion				32.13	< 0.01			39.96	< 0.01		7.96	< 0.01
No	29	27	2			28	1			35.68 ± 14.04
Yes	89	29	60			26	63			64.93 ± 18.07
Lymph node metastasis				31.85	< 0.01			34.71	< 0.01		8.45	< 0.01
No	34	30	4			30	4			37.60 ± 15.73
Yes	84	26	58			24	60			66.24 ± 17.24
Distant metastasis									< 0.01
No	63	48	15			50	13			42.81 ± 17.23
Liver metastasis	20	4	16	20.48a	< 0.01a	3	17	27.25a	< 0.01a	73.40 ± 8.07	7.65a	< 0.01a
Peritoneal dissemination	35	4	31	34.72b	< 0.01b	1	34	52.77b	< 0.01b	75.79 ± 9.48	10.46b	< 0.01b

^aCompared between patients with liver metastasis and those without distant metastasis.

^bCompared between patients with peritoneal dissemination and those without distant metastasis.

Table 2 Correlation of integrin β3 mRNA, VEGF protein and MVD with survival period

Groups		n	Mean survival period (mo)	t	P	5-yr survival rate (%)	χ2	P
Integrin β3 mRNA	-	56	38.46 ± 29.20	2.27	< 0.05	71.4 (40/56)	5.60	< 0.05
	+ - +++	62	27.18 ± 24.73			11.3 (7/62)
VEGF	-	54	41.70 ± 30.62	3.40	< 0.01	70.4 (16/54)	6.52	< 0.05
	+ - +++	64	24.80 ± 21.78			10.9 (7/64)
MVD (n/mm2)	< 54.90	47	44.70 ± 32.05	3.84	< 0.01	63.8 (17/47)	13.85	< 0.01
	≥ 54.90	71	24.48 ± 20.40			8.5 (6/71)